A Study to Evaluate Treatment Patterns and Effectiveness of Luspatercept

Treatment Patterns and Outcomes in Patients With Lower-risk Myelodysplastic Syndromes Treated With Luspatercept in China

NCT07073690 ·Status: COMPLETED

Study of Luspatercept for the Treatment of Anemia in Patients With Myelodysplastic Syndrome (MDS) (MK-6143-001)

NCT01749514 ·Status: COMPLETED ·Phase: PHASE2

Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome.

NCT05181592 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA

NCT05181735 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions

NCT05384691 ·Status: RECRUITING ·Phase: PHASE2

Extension Study to Evaluate Long-Term Effects of Luspatercept in Patients With Myelodysplastic Syndromes (MDS) (A536-05/MK-6143-003)

NCT02268383 ·Status: COMPLETED ·Phase: PHASE2

Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients

NCT04539236 ·Status: SUSPENDED ·Phase: PHASE1/PHASE2

A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

NCT02631070 ·Status: COMPLETED ·Phase: PHASE3

Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts

NCT05005182 ·Status: TERMINATED ·Phase: PHASE2

Amifostine in Treating Patients With Advanced Myelodysplastic Syndrome

NCT00003123 ·Status: UNKNOWN ·Phase: PHASE2

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

NCT04717414 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Study of Oral Dasatinib in Subjects With Myelodysplastic Syndrome (MDS) and Excess Marrow Blasts

NCT00624585 ·Status: COMPLETED ·Phase: NA

Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)

NCT00255346 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate PT-523 in Patients With Refractory Leukemia

NCT00129558 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2

Multiple Ascending Dose of BMS-911543

NCT01236352 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Dose-escalation Study of Oral Administration of S 055746 in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome

NCT02920541 ·Status: COMPLETED ·Phase: PHASE1

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

NCT04064060 ·Status: RECRUITING ·Phase: PHASE3

Oral Clofarabine Study in Patients With Myelodysplastic Syndrome

NCT00299156 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate the Efficacy, Drug Levels and Safety of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Chinese and Japanese Participants With Ring Sideroblasts Who Require Red Blood Cell Transfusions

NCT04477850 ·Status: COMPLETED ·Phase: PHASE2

Erlotinib Study for Myelodysplastic Syndrome (MDS)

NCT00977548 ·Status: COMPLETED ·Phase: PHASE2

An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes

NCT01381809 ·Status: COMPLETED ·Phase: PHASE3

Biologically Focused Therapy of Treatment-Refractory MDS Patients

NCT05245032 ·Status: COMPLETED

MK0457 in Patients With Leukemia (0457-003)

NCT00111683 ·Status: COMPLETED ·Phase: PHASE1

Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)

NCT02093429 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

NCT01895842 ·Status: COMPLETED ·Phase: PHASE1